Think of GLP-1s as a spark plug
In our November review, Nutrition Insight highlights some of the months biggest stories, including breakthrough GLP-1 research and drug development, our discussion with AAK on the impact of supply chains on nutrition innovation, and Novonesis latest insights into microbiome-focused healthy longevity innovations
Approved products still require medical oversight Approval does not mean a medicine is right for everyone
Mounjaro is classified as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
However, after Thursdays announcement, just two days later, Hims & Hers announced it will be pulling the plug on its semaglutide pill, sharing a statement from the brand communications teams on X
Regenerons Phase 2 COURAGE trial echoed these results in humans: combination therapy significantly reduced fat while preserving up to 81% of lean mass loss compared to semaglutide alone